Seer
Seer Medical is a Melbourne-based medical technology company that provides clinical-grade at-home video-EEG-ECG monitoring for epilepsy diagnosis and management, serving neurologists, hospitals, and epilepsy patients across Australia, the US, and UK through wearable devices, a cloud platform, and a patient app.
- Company typePrivate
- Founded2016
- HeadquartersRochester, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
What Seer does
Seer Medical is a privately held medical technology company headquartered in Carlton, Melbourne, Australia, that provides clinical-grade at-home video-EEG-ECG monitoring for epilepsy diagnosis and management. Founded with the mission of transitioning clinical neurological monitoring from the hospital to the home, Seer has built a vertically integrated platform spanning proprietary wearable hardware (the Seer Sense shoulder-mounted EEG device with telescopic pole-mounted camera), a cloud data platform (Seer Cloud) for clinician review, and a patient-facing mobile application (Seer Medical App). The company's stated evidence base covers 20,000+ monitored patients and 70+ peer-reviewed research publications demonstrating diagnostic-quality data capture (99.83% EEG amplifier availability, 94.90% video capture rate during events).
The technology stack combines miniaturized wearable biosensors with deep learning — including LSTM networks for motor seizure detection (mean AUC 0.98), ECG-based seizure detection (AUROC 0.91), CNNs for epileptic discharge detection (95% sensitivity), and multimodal forecasting models using critical slowing features (prospective AUC 0.77). These AI capabilities are validated through ongoing clinical research rather than licensed from third parties. Seer also operates a diagnostic screening NLP tool that distinguishes epilepsy from functional neurological disorder, syncope, and other paroxysmal conditions.
Seer earns revenue through three streams: diagnostic monitoring services provided to patients on referral from neurologists and hospitals, subscription access to the Seer Cloud platform for clinicians, and the provision of wearable hardware on loan during monitoring studies. The go-to-market is enterprise field sales into hospitals and neurology clinics, supplemented by clinical referrals and a research-led content marketing approach. The company holds HIPAA, GDPR, and Australian Privacy Principles compliance, with wholly-owned subsidiaries in the United States (Seer Medical LLC), United Kingdom (Seer Medical UK Pty Ltd), and Germany (Seer Deutschland GmbH as EU representative). Funding to date includes a 2021 Series A of approximately A$24.9M led by Cochlear, a 2022 investment from Breakthrough Victoria with support from the Andrews Labor Government, and a 2025 strategic investment from US neurodiagnostics distributor Cadwell Laboratories.
Seer firmographics
Firmographics- Name
- Seer
- Legal name
- Seer Medical Holdings Limited
- Website
- https://seermedical.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Seer Medical is a Melbourne-based medical technology company that provides clinical-grade at-home video-EEG-ECG monitoring for epilepsy diagnosis and management, serving neurologists, hospitals, and epilepsy patients across Australia, the US, and UK through wearable devices, a cloud platform, and a patient app.
- Ownership category
- akta.pro rank
Seer industry classification
Industry- Product category
- Epilepsy Diagnostic Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
Keywords
Where Seer is headquartered
LocationHeadquarters
- HQ city
- Rochester
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Seer business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Diagnostic Monitoring Services: Home-based EEG-ECG-VIDEO monitoring services for epilepsy diagnosis and management. Patients undergo monitoring studies with loaned equipment, with data reviewed by medical professionals for diagnostic purposes.
- Software Platform (Seer Cloud & App): Cloud platform and mobile application providing data storage, review capabilities, seizure tracking, and insights for patients and healthcare providers. Licensed access through subscription model.
- Medical Device Provision: Wearable monitoring devices (Seer Sense) provided on loan during monitoring periods. Device technology integrated with service delivery model for clinical monitoring.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Seer product offering
Product offeringCore offering
Seer Medical develops wearable EEG-ECG-VIDEO monitoring devices (Seer Sense) and a cloud platform (Seer Cloud) with a mobile app (Seer Medical App) that enable clinical-grade at-home video-EEG-ECG monitoring for epilepsy diagnosis and management. The platform combines wearable biosignal hardware, cloud-based data storage and review, and AI-powered seizure detection and forecasting algorithms to transition clinical monitoring from hospital to home.
Product overview
Seer Medical offers a unified platform combining wearable devices, cloud computing, and mobile applications for at-home epilepsy diagnosis and monitoring. The core product portfolio includes: (1) Seer Sense, a wearable shoulder-worn EEG-ECG-video monitoring device; (2) Seer Cloud, a cloud platform for EEG-ECG data storage and healthcare provider review; (3) the Seer Medical App, a mobile application for patients to track seizures, medications, and access seizure risk forecasts; and (4) Seizure Risk Forecasting, machine learning algorithms that predict seizure likelihood. The Seer Home System is under development and not yet commercially available. The platform enables the transition of clinical monitoring from hospital to home, with AI-powered seizure detection and forecasting capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Seer Sense: Wearable EEG-ECG monitoring device designed for at-home epilepsy diagnosis and monitoring
- Seer Home System
- Seer Cloud
- Seer Medical App
Products and services
- Seer Sense
Quantifiable outcome
- 99.83% EEG amplifier availability during events
- +4 more outcomes
Companies that use Seer
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Seer technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature7 records
Seer partnerships and signals
Strategic signalScale indicators6 records
Recent moves9 records
Expansion highlights7 records
Seer competitors and assessment
Company assessmentDirect peers
- Empatica: Empatica makes the Embrace2/Embrace Plus wearable, an FDA-cleared smartwatch-class device for seizure detection in epilepsy patients. It is the closest direct competitor to Seer Sense in the at-home seizure monitoring category, targeting the same patient population with a more consumer-grade form factor.
- Ceribell: Ceribell provides AI-powered point-of-care EEG (the Ceribell EEG Headband and Clarity algorithm) for rapid seizure detection in hospital settings. It shares Seer's AI-on-EEG technology foundation and overlapping neurology customer base, but is focused on inpatient rather than home monitoring.
- NeuroPace: NeuroPace markets the RNS System, an FDA-approved closed-loop responsive neurostimulator for drug-resistant epilepsy. It is a direct epilepsy-neurotech competitor addressing the same patient population with an implantable approach versus Seer's non-invasive home monitoring strategy.
- BioSerenity: BioSerenity develops wearable EEG headsets and remote neurology monitoring services for epilepsy and sleep disorders. It competes head-to-head with Seer in at-home EEG monitoring and shares the same service-plus-device, clinician-referral business model.
- Cadwell Industries: Cadwell manufactures clinical EEG, EMG, and intraoperative neurodiagnostic equipment sold to hospitals and neurology practices. Cadwell is also a disclosed strategic investor in Seer (2025 round), making it both a competitor in the EEG systems category and a channel partner.
- Compumedics: Compumedics is an Australia-headquartered neurodiagnostic equipment manufacturer (EEG, sleep, PSG systems) competing in the same clinical EEG systems category as Seer. Comparable in geography and core customer base, providing a relevant ANZ-market reference point.
Broad incumbents
- Natus Medical: Natus is an established global manufacturer of neurodiagnostic and EEG systems used by hospitals and neurology clinics. As a broad incumbent in the EEG equipment category, it competes with Seer for hospital neurology budgets but lacks a home-monitoring product line.
- Medtronic: Medtronic offers deep brain stimulation (Activa) for epilepsy and broader neurology products through its CNS portfolio. As a large incumbent medtech, it represents the type of strategic competitor that could bundle or build a competing home-EEG offering if home monitoring becomes standard of care.
- Boston Scientific: Boston Scientific's Vercise deep brain stimulation system targets Parkinson's with emerging epilepsy indications. As a large incumbent neuromodulation player, it competes in the broader epilepsy treatment pathway and could expand into adjacent home-monitoring offerings.
Emerging players
- iRhythm Technologies: iRhythm operates the Zio long-term wearable cardiac monitoring service, sharing Seer's device-plus-AI-service business model and clinical-referral go-to-market. It is a partial analogue demonstrating how a wearable diagnostics service can scale into a public company, though applied to cardiac rather than neurological indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Seer social profiles
Digital presenceSeer compliance and trust
Trust signalCompliance3 records
Seer financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seer leadership team
Management profileNumber of profiles
Profiles6 records
Seer subsidiaries and ownership
Company hierarchySubsidiaries3 records
Seer funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seer M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seer
What does Seer do?
Seer Medical develops wearable EEG-ECG-VIDEO monitoring devices (Seer Sense) and a cloud platform (Seer Cloud) with a mobile app (Seer Medical App) that enable clinical-grade at-home video-EEG-ECG monitoring for epilepsy diagnosis and management. The platform combines wearable biosignal hardware, cloud-based data storage and review, and AI-powered seizure detection and forecasting algorithms to transition clinical monitoring from hospital to home.
Is Seer a public or private company?
Seer is a private company. It is classified as venture growth investor backed and is currently operating.
When was Seer founded?
Seer was founded in 2016. It employs 1 to 10 people.
Where is Seer based?
Seer is headquartered in Rochester, United States, in the North America region.
How does Seer make money?
Three revenue lines are on record. Diagnostic Monitoring Services are the primary driver. The others are software Platform (Seer Cloud & App) and medical Device Provision.
Who are Seer's main competitors?
Direct peers on record are Empatica, Ceribell, NeuroPace, BioSerenity, Cadwell Industries and Compumedics. Broad incumbents are Natus Medical, Medtronic and Boston Scientific. iRhythm Technologies is listed as an emerging player.
Does Seer have an API?
No public API is recorded for Seer.
What industry is Seer in?
Seer's product category is Epilepsy Diagnostic Monitoring. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3841.